Stentectomy for LAD “full metal jacket” with in‐stent restenosis: How to do it

2021 ◽  
Author(s):  
Carlo Maria Rosati ◽  
Samin K. Sharma ◽  
Michael J. Robbins ◽  
Aarti Patil ◽  
Minh Quan Vu ◽  
...  
Keyword(s):  
Stent Restenosis ◽  
Full Metal Jacket ◽  
In Stent Restenosis

Management of recurrent in-stent restenosis: onion skin full metal jacket?

2013 ◽  
Vol 9 (7) ◽  
pp. 781-785 ◽  
Author(s):  
Fernando Alfonso ◽  
Bruno Scheller
Keyword(s):  
Stent Restenosis ◽  
Onion Skin ◽  
Full Metal Jacket ◽  
In Stent Restenosis

Drug-eluting Balloons in Coronary Artery Disease – Current and Future Perspectives

2012 ◽  
Vol 8 (1) ◽  
pp. 56 ◽  
Author(s):  
Anouar Belkacemi ◽  
Pierfrancesco Agostoni ◽  
Michiel Voskuil ◽  
Pieter Doevendans ◽  
Pieter Stella ◽  
...  
Keyword(s):  
Small Vessel Disease ◽  
Percutaneous Treatment ◽  
Added Value ◽  
High Concentration ◽  
Diffuse Disease ◽  
Stent Restenosis ◽  
Alternative Treatment Option ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Percutaneous treatment of complex coronary lesions, such as small-vessel disease, diabetes and long diffuse disease, remain hampered by suboptimal results, even with the use of drug-eluting stents (DES). The paclitaxel drug-eluting balloon (DEB) is an interesting emerging device that optimises clinical outcomes in these specific lesions. The DEB may become a viable alternative treatment option for the inhibition of coronary restenosis and subsequent revascularisation, as it allows local release of a high-concentration antirestenotic drug, paclitaxel, into the coronary vessel without using a metal scaffold or durable polymers. Several studies have already shown promising and consistent results in the treatment of in-stent restenosis. The DEB has demonstrated its added value compared with certain DES. Inspired by these results, an increasing number of studies have been started in different coronary lesion subsets to explore the value of the DEB in a broader range of lesions. It will be interesting to see whether the DEB will find more indications beyond in-stent restenosis treatment. Moreover, will all DEBs offer the same added value, or will there be differences in efficacy among the DEBs produced by the various manufacturers? As was the case in the development of DES, now the puzzle pieces have to be put together for DEB.

Endovascular Brachytherapy for Prevention of Recurrent Renal In-Stent Restenosis

2002 ◽  
Vol 9 (3) ◽  
pp. 350-353 ◽  
Author(s):  
Sandra Stoeteknuel-Friedli ◽  
Dai-Do Do ◽  
Christian von Briel ◽  
Jürgen Triller ◽  
Felix Mahler ◽  
...  
Keyword(s):  
Endovascular Brachytherapy ◽  
Stent Restenosis ◽  
In Stent Restenosis
Sign in / Sign up

Export Citation Format

Share Document